Mereo BioPharma Group PLC ADR (MREO)vsModerna Inc (MRNA)
MREO
Mereo BioPharma Group PLC ADR
$0.28
+14.47%
HEALTHCARE · Cap: $42.67M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
MREO leads profitability with a 0.0% profit margin vs -141.4%. MREO earns a higher WallStSmart Score of 26/100 (F).
MREO
Avoid26
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MREO.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MREO
The strongest argument for MREO centers on Debt/Equity, Price/Book.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : MREO
The primary concerns for MREO are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
MREO profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
MREO generates stronger free cash flow (-6M), providing more financial flexibility.
Bottom Line
MREO scores higher overall (26/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Mereo BioPharma Group PLC ADR
HEALTHCARE · BIOTECHNOLOGY · USA
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops and markets therapeutic products for the treatment of oncology and rare diseases in the UK and internationally. The company is headquartered in London, the United Kingdom.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?